The stock of Endocyte, Inc. (NASDAQ:ECYT) hit a new 52-week low and has $2.37 target or 12.00% below today’s $2.69 share price. The 7 months bearish chart indicates high risk for the $114.31 million company. The 1-year low was reported on Nov, 3 by Barchart.com. If the $2.37 price target is reached, the company will be worth $13.72M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 70,069 shares traded hands. Endocyte, Inc. (NASDAQ:ECYT) has declined 15.60% since April 1, 2016 and is downtrending. It has underperformed by 16.81% the S&P500.
Endocyte, Inc. (NASDAQ:ECYT) Ratings Coverage
Out of 2 analysts covering Endocyte (NASDAQ:ECYT), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Endocyte has been the topic of 3 analyst reports since August 5, 2015 according to StockzIntelligence Inc. On Wednesday, November 4 the stock rating was maintained by RBC Capital Markets with “Outperform”. RBC Capital Markets maintained the shares of ECYT in a report on Wednesday, August 5 with “Outperform” rating. As per Thursday, January 21, the company rating was initiated by Credit Suisse.
According to Zacks Investment Research, “Endocyte, Inc. is a biopharmaceutical company engaged in the development of therapies for the treatment of cancer and inflammatory diseases. The Company creates novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. Endocyte, Inc. is based in West Lafayette, Indiana.”
Insitutional Activity: The institutional sentiment decreased to 0.87 in 2016 Q2. Its down 0.25, from 1.12 in 2016Q1. The ratio fall, as 10 funds sold all Endocyte, Inc. shares owned while 29 reduced positions. 9 funds bought stakes while 25 increased positions. They now own 15.26 million shares or 5.31% less from 16.12 million shares in 2016Q1.
Concannon Wealth Limited Liability Com last reported 0.11% of its portfolio in the stock. Citadel Advsr Ltd Llc accumulated 0% or 24,718 shares. Northern Tru holds 0% of its portfolio in Endocyte, Inc. (NASDAQ:ECYT) for 380,059 shares. The Pennsylvania-based Susquehanna Intl Gp Limited Liability Partnership has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). 1St Source State Bank last reported 32,942 shares in the company. Kcg Hldg has 0% invested in the company for 26,180 shares. Employees Retirement System Of Texas owns 136,000 shares or 0.01% of their US portfolio. Hilltop Holdg Inc accumulated 10,720 shares or 0.01% of the stock. Alliancebernstein Ltd Partnership last reported 0% of its portfolio in the stock. Parametric Port Assocs Limited Com holds 19,857 shares or 0% of its portfolio. Moreover, Voya Limited Liability Corporation has 0% invested in Endocyte, Inc. (NASDAQ:ECYT) for 23,200 shares. Tower Research Cap Ltd Liability Co (Trc) owns 4,466 shares or 0% of their US portfolio. Moreover, Morgan Stanley has 0% invested in Endocyte, Inc. (NASDAQ:ECYT) for 75,887 shares. Blackrock Investment Mngmt Limited Company holds 0% or 159,905 shares in its portfolio. Trust Department Mb Bancorp N A last reported 0% of its portfolio in the stock.
Insider Transactions: Since May 10, 2016, the stock had 1 buy, and 0 insider sales for $40,040 net activity. On Tuesday, May 10 Low Philip S bought $40,040 worth of the stock or 11,375 shares.
More important recent Endocyte, Inc. (NASDAQ:ECYT) news were published by: Medgadget.com which released: “Endocyte, Inc Clinical Trial Review, Market Size, Segment, Trends and Forecast …” on November 01, 2016, also Ibj.com published article titled: “CEO Ellis resigns after 20 years at struggling drug firm Endocyte”, Zacks.com published: “Endocyte (ECYT): Can the Stock Surprise in Q3 Earnings?” on October 28, 2016. More interesting news about Endocyte, Inc. (NASDAQ:ECYT) was released by: Fool.com and their article: “Why Endocyte, Inc. Stock Briefly Spiked Higher” with publication date: September 29, 2014.
ECYT Company Profile
Endocyte Inc. (Endocyte), incorporated on December 11, 2001, is a biopharmaceutical company. The Firm is engaged in developing therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), PSMA Tubulysin (EC1169), Vintafolide (Folate DAVLBH), Folate-DNA alkylator (EC1788), Folate-Aminopterin (EC1669), Folate-mTor inhibitor (EC0371), Etarfolatide (Folcepri or Tc99m) and PSMA- Tc99m (EC0652).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.